drugset / Trial / NCT03128593
A Study of JR-141 in Patients With Mucopolysaccharidosis Type II
NaSequentialOpen-labelTreatment
Summary
The purpose of this study in patients with mucopolysaccharidosis type II (MPS II) is below, * to collect the safety information of JR-141 * to evaluate the plasma pharmacokinetics of JR-141 * to explore the efficacy of JR-141 on MPS II-related central nervous system symptoms and general symptoms
Timeline
- Start
- 2017-03-30
- Primary completion
- 2017-10-04
- Completion
- 2017-10-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PABINAFUSP ALFA | Protein / enzyme biologic | 0.01 mg/kg | Intravenous |
| Subject | PABINAFUSP ALFA | Protein / enzyme biologic | 2 mg/kg | Intravenous |